PULMONARY FIBROSIS

This study tests whether sirolimus, a drug used to prevent organ rejection, can reduce the risk of lung scarring (fibrosis) in people hospitalized with severe COVID-19 pneumonia. About 60 adults will receive sirolimus to see if it prevents long-term lung damage. The goal is to im…

This early-phase trial tests a nebulized protein from donated fat cells in 7 adults with pulmonary fibrosis, a lung-scarring disease. Participants inhale the treatment every 3 days for 7 doses. The study measures changes in breathing, cough, and quality of life, and checks for si…

This study is testing a new inhaled treatment for pulmonary fibrosis, a condition where the lungs become scarred and stiff. The treatment uses tiny fat bubbles (liposomes) coated with a substance that helps them target the cells causing inflammation and scarring. The goal is to s…

This study collects blood, lung tissue, and other samples from people with pulmonary fibrosis, their relatives, and healthy volunteers. Researchers analyze these samples to learn what causes the disease and how it progresses. No treatments or medications are tested. The goal is t…

This study looks at 200 people with both lung cancer and a lung scarring condition called pulmonary fibrosis. Researchers want to see how well immunotherapy (a type of cancer treatment) works in these patients and if it causes more side effects. They will also study tumor samples…

This study looks at 200 people with severe COVID-19 who needed intensive care to see how often they develop lung scarring (pulmonary fibrosis). Researchers will track their recovery, including time off a breathing machine and survival at 90 days, to understand risk factors and ou…

This study follows 500 adults who had COVID-19 to learn about long-term health issues like tiredness, shortness of breath, and lung scarring. Researchers will track recovery patterns and identify who is most at risk for lasting problems. No new treatments are tested; the goal is …

This study follows 157 adults with pulmonary fibrosis who are taking nintedanib and taking part in a special support program in Spain. Researchers will measure how satisfied patients are with the program, and track their quality of life, mood, and symptoms over 12 months. The goa…

This study looks at lung tissue from 80 people with pulmonary fibrosis to find unique genetic markers of scarring. Researchers hope these markers will lead to better diagnosis and treatment. Participants must be 18 or older and already scheduled for a lung biopsy.

This study aims to understand how common short telomeres are in Israeli adults with fibrotic interstitial lung disease (lung scarring). Researchers will take blood samples from 100 participants and follow their health for two years. No new treatments are tested; the goal is to ga…